Literature DB >> 11921123

Tyrosine hydroxylase deficiency: clinical manifestations of catecholamine insufficiency in infancy.

Padraic J Grattan-Smith1, Ron A Wevers, Gerry C Steenbergen-Spanjers, Victor S C Fung, John Earl, Bridget Wilcken.   

Abstract

Inborn errors of catecholamine biosynthesis are rare but of great interest as they are genetic disorders, and in some, treatment may completely reverse severe neurological abnormalities. They also provide insights into the action of the biogenic amines in the developing brain. We describe the clinical course of an infant with tyrosine hydroxylase (TOH) deficiency over a 30-month period. The parents are consanguineous, and genetic analysis revealed the infant to be homozygous for the common G698A mutation in the TOH gene. TOH deficiency can be seen as a model of pure catecholamine deficiency. Experimental evidence, reports of other disorders of biogenic amines, and our experience with this infant suggest that the symptoms of catecholamine deficiency in infancy can be broadly subdivided. Signs of dopamine deficiency include tremor, hypersensitivity to levadopa (L-dopa) therapy, oculogyric crises, akinesia, rigidity, and dystonia. Manifestations of norepinephrine deficiency include ptosis, miosis, profuse oropharyngeal secretions, and postural hypotension. Hypersensitivity to L-dopa was a particular management problem in this infant. Copyright 2002 Movement Disorder Society.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11921123     DOI: 10.1002/mds.10095

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  15 in total

Review 1.  Heterogeneity of dopamine release sites in health and degeneration.

Authors:  Joseph J Lebowitz; Habibeh Khoshbouei
Journal:  Neurobiol Dis       Date:  2019-11-05       Impact factor: 5.996

2.  Diagnosis and treatment of neurotransmitter disorders.

Authors:  Phillip L Pearl; Thomas R Hartka; Jacob Taylor
Journal:  Curr Treat Options Neurol       Date:  2006-11       Impact factor: 3.598

3.  Levodopa is not a useful treatment for Lesch-Nyhan disease.

Authors:  Jasper E Visser; David J Schretlen; Bastiaan R Bloem; Hyder A Jinnah
Journal:  Mov Disord       Date:  2011-01-31       Impact factor: 10.338

4.  A new tyrosine hydroxylase genotype with orofacial dyskinaesia.

Authors:  Ahood M Al-Muslamani; Fouad Ali; Fatima Mahmood
Journal:  Sultan Qaboos Univ Med J       Date:  2014-07-24

Review 5.  The phenotypic spectrum of paediatric neurotransmitter diseases and infantile parkinsonism.

Authors:  R Pons
Journal:  J Inherit Metab Dis       Date:  2008-12-26       Impact factor: 4.982

Review 6.  Movement disorders in children: recent advances in management.

Authors:  Emilio Fernández-Alvarez
Journal:  Indian J Pediatr       Date:  2009-05-24       Impact factor: 1.967

Review 7.  Genetics of monoamine neurotransmitter disorders.

Authors:  Wai-Kwan Siu
Journal:  Transl Pediatr       Date:  2015-04

Review 8.  Pediatric neurotransmitter diseases.

Authors:  Phillip L Pearl; Denise D Wallis; K Michael Gibson
Journal:  Curr Neurol Neurosci Rep       Date:  2004-03       Impact factor: 5.081

9.  Myoclonus-dystonia syndrome due to tyrosine hydroxylase deficiency.

Authors:  Maria Stamelou; Niccolo E Mencacci; Carla Cordivari; Amit Batla; Nick W Wood; Henry Houlden; John Hardy; Kailash P Bhatia
Journal:  Neurology       Date:  2012-07-18       Impact factor: 9.910

Review 10.  Spotlight on Oculogyric Crisis: A Review.

Authors:  Pankaj Mahal; Navratan Suthar; Naresh Nebhinani
Journal:  Indian J Psychol Med       Date:  2020-09-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.